Silver Biotics - American Biotech Labs
"Powerful Technology Creating Advanced Body & Wound Care"
Executive Summary
Introduction
Clifton Mining Company owns 27% of American Biotech Labs, a private biotech
company. American Biotech Labs has created an advanced antimicrobial technology
utilizing silver as the active ingredient. Using this new patented technology,
American Biotech Labs (ABL) has engineered a number of new products. Some of
these new products have already hit the market, others are awaiting government
approvals. Two patents have already been issued on the new technology and
numerous other patents are pending, including both product and use patents. ABL
has products that are being sold internationally in a number of countries. ABL
has been and is involved in numerous product studies with U.S. Government
agencies, major universities, and also both domestic and international
laboratories.
To date, ABL has released data on two products and a third anticipated to be
released shortly. The products include; a fully-approved hospital disinfectant
called ASAP-AGX-32®; a 10 ppm supplement product sold under both the ASAP
Solution® and also Silver Biotics® labels; and a new product yet to be released
called AGX-SILGEL®, which is an advanced wound care product.
ASAP-AGX-32®
The ASAP-AGX-32® product is a fully EPA-approved surface disinfectant product.
The product is non-caustic, has no color, no smell, and needs no refrigeration.
To date the ASAP-AGX-32® product is approved for use in:
* Hospital operating rooms.
* Any medical facility.
* Industrial facilities.
* Commercial facilities.
* Residential or home uses.
The ASAP-AGX-32® is approved to kill:
* Gram-negative bacteria (i.e. Salmonella choleraesuis).
* Gram-positive bacteria (i.e. Staphylococcus aureus)(called the deadliest
bacteria in the U.S.).
* Nosocomial bacteria pathogen (i.e. Pseudomonas aeruginosa)(known as "hospital
super bugs").
Other Important Features And Information Regarding The ASAP-AGX-32® Product
* ABL has continued its testing of the ASAP-AGX-32® product with the intent to
further expand its disinfectant uses. Preliminary microbial testing that has
been completed, but for which the product has not yet been governmentally
approved, includes resistant bacteria (called superbugs)and even possible
bioweapons, including: MRSA 1, MRSA 2, Anthrax, Y. Pestis or Bubonic Plague,
five different pathogenic strains of Streptococcus, E. coli, Salmonella, yeasts
and even a number of deadly viruses including SARS, etc.
* One of the outstanding features of the ASAP-AGX-32® product is that it has
the proven ability to be a broad-spectrum antimicrobial, while remaining
completely non-toxic to humans at recommended use levels. Because of this
strategic advantage, American Biotech Labs management decided to extend this
extraordinary technology into new medical applications, by using the
ASAP-AGX-32® as the base for creating a new burn and wound-care product.
Through extensive research and testing over the past year-and-a-half, the
company has developed the powerful ASAP- AGX-32® product into the new AGX
SILGEL® product. The testing and efficacy work has already been completed on
the AGX SILGEL® product.
Silver Biotics ®
Silver Biotics® is the national marketing label for the product also known as
the ASAP Solution®. It is an anti-microbial mineral supplement that has been
and is being tested worldwide in human studies, against pathogens and diseases.
It has been EPA approved as a surface disinfectant but is not currently being
marketed under that label. The product is currently marketed in a number of
countries worldwide and is also available under private labels. Of special
interest are three completed human studies from Africa, which include the oral
use of the product against Malaria. Malaria is currently listed as the second
leading cause of death by infection on the planet. It currently effects
hundreds of millions of people worldwide. Malaria reportedly kills as many as
10,000 people a day in Africa, mostly children. In the three completed human
studies, the product has shown great promise as an effective and low-cost
treatment for the disease. Further testing is already underway in two countries
of Africa. ABL is working with a number of international humanitarian groups
that may be able to use the product to help people in the countries where it is
needed.
AGX SILGEL®
The AGX SILGEL® product is a highly advanced wound-care product. It has been
filed for approval with the US FDA for a number of wound-care treatments. It is
expected that the product will be approved for sale by the FDA in 2005. The AGX
SILGEL® product was created with all the antimicrobial Killing ability of the
ASAP-AGX-32® product, but with some additional strategic advantages.
Advantages of the AGX SILGEL® Product
* AGX SILGEL® is a proven broad-spectrum anti-microbial.
* AGX SILGEL® is non-cytotoxic.
* AGX SILGEL® provides moisture for wound healing and burn treatment, and can
be used on or in conjunction with any bandage already available in any
first-aid medical kit.
* AGX SILGEL® has no color, little smell, and needs no refrigeration.
* AGX SILGEL® will remain stable from 17 to 113 degrees Fahrenheit.
* AGX SILGEL® was proven non-toxic in oral route, mouse-model studies at up to
5000 mg/kg. body weight.
* AGX SILGEL® was found non-toxic in oral animal studies at up to 5000ml/kg b.w.
Other Important Features And Information On The AGX SILGEL® Product:
* In FDA approval comparison studies, AGX SILGEL® was found to be over 10 times
more effective at killing the MRSA bacteria (at a challenge of 10,000,000
bacteria per ml) than a leading FDA approved product, even though the leading
product contains over 312 times more of the active ingredient (silver) than the
AGX SILGEL® product.
* AGX SILGEL® is not greasy, contains no alcohol, and if rubbed into the skin,
will absorb within 2 minutes, leaving the skin with a soft, non-sticky feeling.
Continuation
American Biotech Labs, in just a few short years, has been able to develop new
technology into products that have very widespread application. This patented
technology, with the developed products, may be able to save the lives of
literally millions of people here in the U.S. and also abroad. ABL has already
accomplished much in the areas of safe disinfection of hospitals and homes, as
well as in the possible treatment of major disease for third world countries.
ABL is now awaiting government approvals of its new line of wound-care
products, which management believes will be released for public sale in 2005.
ABL, with other strategic partners, is continuing its research and development
of additional new products which are expected to be released in the next few
years.
|
Silver Biotics - American Biotech Labs "Powerful Technology Creating Advanced Body & Wound Care" Executive Summary Introduction Clifton Mining Company owns 27% of American Biotech Labs, a private biotech company. American Biotech Labs has created an advanced antimicrobial technology utilizing silver as the active ingredient. Using this new patented technology, American Biotech Labs (ABL) has engineered a number of new products. Some of these new products have already hit the market, others are awaiting government approvals. Two patents have already been issued on the new technology and numerous other patents are pending, including both product and use patents. ABL has products that are being sold internationally in a number of countries. ABL has been and is involved in numerous product studies with U.S. Government agencies, major universities, and also both domestic and international laboratories. To date, ABL has released data on two products and a third anticipated to be released shortly. The products include; a fully-approved hospital disinfectant called ASAP-AGX-32®; a 10 ppm supplement product sold under both the ASAP Solution® and also Silver Biotics® labels; and a new product yet to be released called AGX-SILGEL®, which is an advanced wound care product. ASAP-AGX-32® The ASAP-AGX-32® product is a fully EPA-approved surface disinfectant product. The product is non-caustic, has no color, no smell, and needs no refrigeration. To date the ASAP-AGX-32® product is approved for use in: * Hospital operating rooms. * Any medical facility. * Industrial facilities. * Commercial facilities. * Residential or home uses. The ASAP-AGX-32® is approved to kill: * Gram-negative bacteria (i.e. Salmonella choleraesuis). * Gram-positive bacteria (i.e. Staphylococcus aureus)(called the deadliest bacteria in the U.S.). * Nosocomial bacteria pathogen (i.e. Pseudomonas aeruginosa)(known as "hospital super bugs"). Other Important Features And Information Regarding The ASAP-AGX-32® Product * ABL has continued its testing of the ASAP-AGX-32® product with the intent to further expand its disinfectant uses. Preliminary microbial testing that has been completed, but for which the product has not yet been governmentally approved, includes resistant bacteria (called superbugs)and even possible bioweapons, including: MRSA 1, MRSA 2, Anthrax, Y. Pestis or Bubonic Plague, five different pathogenic strains of Streptococcus, E. coli, Salmonella, yeasts and even a number of deadly viruses including SARS, etc. * One of the outstanding features of the ASAP-AGX-32® product is that it has the proven ability to be a broad-spectrum antimicrobial, while remaining completely non-toxic to humans at recommended use levels. Because of this strategic advantage, American Biotech Labs’ management decided to extend this extraordinary technology into new medical applications, by using the ASAP-AGX-32® as the base for creating a new burn and wound-care product. Through extensive research and testing over the past year-and-a-half, the company has developed the powerful ASAP- AGX-32® product into the new AGX SILGEL® product. The testing and efficacy work has already been completed on the AGX SILGEL® product. Silver Biotics ® Silver Biotics® is the national marketing label for the product also known as the ASAP Solution®. It is an anti-microbial mineral supplement that has been and is being tested worldwide in human studies, against pathogens and diseases. It has been EPA approved as a surface disinfectant but is not currently being marketed under that label. The product is currently marketed in a number of countries worldwide and is also available under private labels. Of special interest are three completed human studies from Africa, which include the oral use of the product against Malaria. Malaria is currently listed as the second leading cause of death by infection on the planet. It currently effects hundreds of millions of people worldwide. Malaria reportedly kills as many as 10,000 people a day in Africa, mostly children. In the three completed human studies, the product has shown great promise as an effective and low-cost treatment for the disease. Further testing is already underway in two countries of Africa. ABL is working with a number of international humanitarian groups that may be able to use the product to help people in the countries where it is needed. AGX SILGEL® The AGX SILGEL® product is a highly advanced wound-care product. It has been filed for approval with the US FDA for a number of wound-care treatments. It is expected that the product will be approved for sale by the FDA in 2005. The AGX SILGEL® product was created with all the antimicrobial Killing ability of the ASAP-AGX-32® product, but with some additional strategic advantages. Advantages of the AGX SILGEL® Product * AGX SILGEL® is a proven broad-spectrum anti-microbial. * AGX SILGEL® is non-cytotoxic. * AGX SILGEL® provides moisture for wound healing and burn treatment, and can be used on or in conjunction with any bandage already available in any first-aid medical kit. * AGX SILGEL® has no color, little smell, and needs no refrigeration. * AGX SILGEL® will remain stable from 17 to 113 degrees Fahrenheit. * AGX SILGEL® was proven non-toxic in oral route, mouse-model studies at up to 5000 mg/kg. body weight. * AGX SILGEL® was found non-toxic in oral animal studies at up to 5000ml/kg b.w. Other Important Features And Information On The AGX SILGEL® Product: * In FDA approval comparison studies, AGX SILGEL® was found to be over 10 times more effective at killing the MRSA bacteria (at a challenge of 10,000,000 bacteria per ml) than a leading FDA approved product, even though the leading product contains over 312 times more of the active ingredient (silver) than the AGX SILGEL® product. * AGX SILGEL® is not greasy, contains no alcohol, and if rubbed into the skin, will absorb within 2 minutes, leaving the skin with a soft, non-sticky feeling. Continuation American Biotech Labs, in just a few short years, has been able to develop new technology into products that have very widespread application. This patented technology, with the developed products, may be able to save the lives of literally millions of people here in the U.S. and also abroad. ABL has already accomplished much in the areas of safe disinfection of hospitals and homes, as well as in the possible treatment of major disease for third world countries. ABL is now awaiting government approvals of its new line of wound-care products, which management believes will be released for public sale in 2005. ABL, with other strategic partners, is continuing its research and development of additional new products which are expected to be released in the next few years. |
